Generation Bio Co. (GBIO) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
GBIO currently has 6.74M outstanding shares. with significant dilution risk as 11.6M authorized shares could dilute existing holders by 171.5%. The company has minimally diluted shareholders by 1.4% over the past 2 years. Recent corporate actions include 1 stock split (positive for accessibility) and 1 reverse split (concerning signal).
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 05, 2025 |
10-Q filing | 6.7M shares outstanding |
6.7M | 12M |
| Aug 12, 2025 |
10-Q filing | 6.7M shares outstanding |
6.7M | 12M |
| Jul 21, 2025 |
Stock Split
8-K filing: Stock split 1-for-10 | Outstanding: 67,002,511 → 6,700,251 |
6.7M | 12M |
| May 07, 2025 |
10-Q filing | 67.0M shares outstanding |
67M | 120M |
| Mar 13, 2025 |
10-K filing | 66.6M shares outstanding |
67M | 120M |
| Jan 06, 2025 |
8-K filing: Election of Phillip Samayoa as Chief Scientific Officer and the reduction in the Company's workforce by approximately 20%. |
67M | 120M |
| Nov 06, 2024 |
10-Q filing | 66.7M shares outstanding |
67M | 120M |
| Aug 07, 2024 |
S-3 filing: Generation Bio Co. is offering securities from time to time in one or more offerings of up to $600,000,000 in aggregate offering price. |
67M | 120M |
| Aug 07, 2024 |
10-Q filing | 66.5M shares outstanding |
67M | 120M |
| May 13, 2024 |
10-Q filing | 66.4M shares outstanding |
66M | 19M |
| Mar 06, 2024 |
10-K filing | 64.5M shares outstanding |
64M | 19M |
| Nov 09, 2023 |
10-Q filing | 65.9M shares outstanding |
66M | 19M |
| Aug 02, 2023 |
10-Q filing | 65.7M shares outstanding |
66M | 19M |
| May 10, 2023 |
10-Q filing | 60.2M shares outstanding |
60M | 19M |
| Mar 23, 2023 |
8-K filing: Generation Bio Co. sold and issued 5,859,375 shares of its common stock to Moderna at an aggregate purchase price of $36.0 million in a completed transaction. ($36.0M proceeds) |
58M | 19M |
| Feb 23, 2023 |
10-K filing | 58.1M shares outstanding |
58M | 19M |
| Nov 03, 2022 |
10-Q filing | 58.9M shares outstanding |
59M | 19M |
| Aug 04, 2022 |
10-Q filing | 57.1M shares outstanding |
57M | 19M |
| May 05, 2022 |
10-Q filing | 57.0M shares outstanding |
57M | 19M |
| Feb 24, 2022 |
10-K filing | 56.3M shares outstanding |
56M | 19M |
| Feb 24, 2022 |
POS AM filing: Generation Bio Co. files a POS AM to offer and sell up to $600,000,000 in the aggregate of securities from time to time in one or more offerings including Debt Securities, Common Stock, and Preferred Stock. |
57M | 19M |
| Nov 10, 2021 |
10-Q filing | 56.9M shares outstanding |
57M | 19M |
| Aug 11, 2021 |
10-Q filing | 56.8M shares outstanding |
57M | 19M |
| May 12, 2021 |
10-Q filing | 56.6M shares outstanding |
57M | 19M |
| Mar 18, 2021 |
10-K filing | 46.3M shares outstanding |
46M | 19M |
| Jan 04, 2021 |
S-1 filing: This S-1 filing from 2021-01-04 details an offering of common stock with a proposed amount of $199.2 million and outlines the company's intention to use the net proceeds for research and development of their programs, platform technologies, and general corporate purposes. |
54M | 19M |
| Nov 10, 2020 |
10-Q filing | 45.6M shares outstanding |
46M | 11M |
| Aug 11, 2020 |
10-Q filing | 5.3M shares outstanding |
5.3M | 11M |
| Jun 11, 2020 |
S-1/A filing: This S-1/A filing outlines a proposed offering of common stock with an option for underwriters to purchase additional shares, intended for research and development, platform technology enhancement, and general corporate purposes. |
7M | 11M |
| Jun 08, 2020 |
S-1/A filing: This S-1/A filing details an offering of common stock, with 7,400,000 shares offered by the company and an option for underwriters to purchase an additional 1,110,000 shares, resulting in 41,508,104 shares outstanding after the offering, and includes information about executive compensation and agreements. |
7M | 15M |